Not sure about that.  

The way I look at it, a drug that does not increase eGFR is useless for CKD.  I mean what will any doctor with such a drug re CKD?

So I focus only on thet % increase in eGFR and will look to see if it is statistically significant.  Based on Phase 2 data, the length of the trial and the # of CKD patients involved, statistical significance should be very obvous.